This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
BAYRYPositive Net Change BEAMPositive Net Change ADMAPositive Net Change MDGLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
BEAMPositive Net Change FOLDPositive Net Change ADMAPositive Net Change BHCPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales
by Zacks Equity Research
United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.
BAYRYPositive Net Change UTHRPositive Net Change BEAMPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas
by Zacks Equity Research
ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas are included in this Analyst Blog.
FCFSNegative Net Change NFGNegative Net Change LRNPositive Net Change ADMAPositive Net Change LTHNegative Net Change
biotechs
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
by Zacks Equity Research
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
BIIBPositive Net Change BEAMPositive Net Change ADMAPositive Net Change SAGEPositive Net Change
biotechs earnings
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
by Zacks Equity Research
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
SNYPositive Net Change GSKPositive Net Change JNJPositive Net Change VIRPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
by Ekta Bagri
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. We advise investors to remain on the sidelines at current levels.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
BEAMPositive Net Change RGENPositive Net Change ADMAPositive Net Change IMCRPositive Net Change
biotechs earnings
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZPositive Net Change AMRXNegative Net Change
biotechs cancer cannabis earnings-preview marijuana medical
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
by Zacks Equity Research
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NVSPositive Net Change LLYNegative Net Change BAYRYPositive Net Change INCYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
by Zacks Equity Research
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
by Zacks Equity Research
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
SNYPositive Net Change AZNPositive Net Change MRKPositive Net Change AMGNNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
3 Unconventional Cannabis Stocks to Watch in 2025
by Sundeep Ganoria
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
PMPositive Net Change JAZZPositive Net Change CRBPNegative Net Change
biotechs marijuana medical pharmaceuticals pot-stocks
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).
VRTXPositive Net Change CTMXNegative Net Change CRSPPositive Net Change ARGXPositive Net Change
biotechs
Can Amgen Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
Volume growth of AMGN's key drugs like Evenity, Repatha and Kyprolis is expected to have been partially offset by biosimilar/generic competition for mature drugs.
AMGNNegative Net Change EXELNegative Net Change BPMCPositive Net Change DNLIPositive Net Change
biotechs
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
REGNPositive Net Change BIIBPositive Net Change PFEPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs pharmaceuticals
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
GSK to Report First-Quarter Earnings: Is a Beat in Store?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.
GSKPositive Net Change JNJPositive Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
NVAXNegative Net Change ZTSNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
AZNPositive Net Change VRTXPositive Net Change EXELNegative Net Change ARGXPositive Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
by Zacks Equity Research
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
RHHBYPositive Net Change JNJPositive Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.
VRTXPositive Net Change BPMCPositive Net Change CTMXNegative Net Change CRSPPositive Net Change
biotechs
Can Moderna Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
MRKPositive Net Change MRNAPositive Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines